Lisata Therapeutics Inc Stock Price, News & Analysis

Lisata Therapeutics (Nasdaq: LSTA) has secured a new composition of matter patent for certepetide from the USPTO, extending protection until March 2040 with potential for further extension. The patent (U.S. Patent No. 12,351,653) covers certepetide's chemical structure, pharmacokinetic properties, manufacturing methods, and applications for treating solid tumor cancers.

This strategic development provides Lisata with the strongest form of IP protection, preventing others from manufacturing or selling the drug. CEO David J. Mazzo emphasized that this patent milestone enhances certepetide's commercial value by delaying generic competition and strengthens the company's position in potential partnership negotiations.

Lisata Therapeutics (NASDAQ:LSTA) announced positive preliminary results from Cohort B of the ASCEND Phase 2b trial evaluating certepetide in metastatic pancreatic cancer. The trial, conducted across 24 sites in Australia and New Zealand, demonstrated significant improvements in patient outcomes.

Key findings include progression-free survival of 60.8% vs 25% (certepetide vs placebo), median progression-free survival of 7.5 vs 4.7 months, and objective response rate of 45.2% vs 19%. Median overall survival improved to 10.32 months vs 9.23 months. The Cohort B regimen, which added a second dose of certepetide, showed meaningful improvements compared to Cohort A's single-dose approach.

Final data from both cohorts is expected later this year, with results suggesting certepetide could potentially transform treatment for metastatic pancreatic cancer, which currently has a five-year survival rate of just 13%.

Lisata Therapeutics (NASDAQ: LSTA) and GATC Health Corp. have expanded their strategic alliance to enhance drug discovery and development using AI technology. The partnership combines Lisata's drug development expertise with GATC's Multiomics Advanced Technology (MAT) platform. A key focus is advancing GATC's AI-discovered therapeutic for opioid use disorder (OUD) into Phase 1 human trials in early 2026. The MAT platform, validated by UC Irvine with 86% sensitivity and 91% specificity, will help identify new combination therapies and predict safety and efficacy. GATC will cover R&D costs while Lisata receives milestone fees and royalties from commercialized products. The collaboration aims to accelerate drug development, potentially reducing discovery time from 5-6 years to one year and creating up to $400 billion in value for the pharmaceutical industry by end-2025.

Lisata Therapeutics (NASDAQ: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and serious diseases, announced its participation in the 2025 BIO International Convention. CEO David J. Mazzo will deliver a corporate overview presentation on Tuesday, June 17th at 11:15 a.m. Eastern Time in Room 153A. The convention will be held in Boston, MA from June 16-19, 2025. Interested parties can register for the conference and schedule one-on-one meetings with Lisata's management team through the BIO convention's registration website.

Lisata Therapeutics (NASDAQ: LSTA) reported Q1 2025 financial results and provided updates on its clinical development portfolio. The company's lead drug certepetide showed encouraging results in multiple trials, including positive trends in the ASCEND trial's Cohort A for pancreatic cancer treatment. Key financial metrics show net losses of $4.7 million for Q1 2025, down from $5.4 million in Q1 2024, with cash reserves of $25.8 million expected to fund operations into Q3 2026. Operating expenses decreased 11.4% to $5.8 million. The company is advancing multiple clinical trials, including ASCEND, BOLSTER, CENDIFOX, and iLSTA, across various solid tumor types. Notably, Cohort B results from the ASCEND trial have been accepted for oral presentation at ESMO-GI 2025, and the company maintains strategic partnerships with Qilu Pharmaceutical, Catalent, and other organizations.

Lisata Therapeutics (NASDAQ: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other serious diseases, has scheduled its Q1 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results.

Participants must pre-register for the conference call through a provided link. A live webcast will be available on Lisata's website under the Investors & News section, with a replay accessible for 12 months following the call.

Lisata Therapeutics (NASDAQ: LSTA) has entered into a research license agreement with Catalent to evaluate the combination of Lisata's certepetide with Catalent's SMARTag® antibody-drug conjugate (ADC) platform for treating advanced solid tumors.

Under the agreement, Catalent will fund all research and development while Lisata provides consulting support. Lisata will receive an upfront payment and potential future considerations based on preclinical evaluation results.

The collaboration aims to enhance ADC therapy by combining certepetide's tumor penetration capabilities with ADC's targeted delivery of cytotoxic drugs. This combination could potentially improve treatment efficacy while reducing systemic toxicity. Additionally, certepetide is expected to reduce the immunosuppressive nature of the tumor microenvironment (TME), potentially improving patient response to ADC therapy.

Lisata Therapeutics, a clinical-stage pharmaceutical company focused on therapies for advanced solid tumors and other serious diseases, announced that its President and CEO, David J. Mazzo, Ph.D., will present at the Investival Showcase USA. The event is scheduled for March 10-11, 2025, in Miami, Florida.

Dr. Mazzo's presentation will occur on March 11th at 11:30 a.m. Eastern Time. For more information about the conference and registration details, please click here.

Lisata Therapeutics (NASDAQ: LSTA) and GATC Health have initiated a strategic collaboration leveraging GATC's AI-powered Multiomics Advanced Technology™ (MAT) platform to optimize and accelerate drug development. The partnership's first phase will analyze Lisata's investigational drug certepetide, focusing on optimizing its Phase 3 development for metastatic pancreatic ductal adenocarcinoma (mPDAC) and identifying new potential indications.

The collaboration will proceed in multiple steps: First, analyzing certepetide's potential applications; second, identifying potential drug combinations across various indications; and finally, establishing Lisata as GATC's operational partner for developing GATC's drug candidates. GATC's MAT AI platform simulates billions of biological interactions to predict safety, efficacy, and clinical trial outcomes.

This partnership aims to address traditional drug development challenges, including high failure rates (1 in 10,000 drugs reach market) and lengthy development timelines, by enabling more focused studies and optimized capital management through AI-driven analysis.